A prosztatarák sebészi kezelése = Surgical treatment of prostate cancer

A prosztatarák a harmadik leggyakoribb férfihalálok Magyarországon. Évente 4500-4800 új beteget ismernek fel, ezzel a hazai incidencia az európai átlag alatt, de a mortalitása jóval felette van, amelyet a korai felismerés hiánya is magyarázhat. Az idejében felismert prosztatarák gyógyítható, az 5 éves túlélés csaknem 100%, míg a metasztatikus formában ez csak 28%. A prosztatarák esetén többféle kezelési lehetőség áll rendelkezésünkre, azonban önmagában gyógyító, és az életkilátást növelő sebészi kezelésként csak a teljes prosztataeltávolítás ajánlható olyan magas rizikóbesorolású betegeknek, akiknek a várható élettartama legalább 10 év. A radikális prostatectomia során eltávolításra kerül a prosztata a tokjával, a kétoldali ondómirigyekkel és a kismedencei nyirokcsomókkal együtt, amely műtéti ellátás során törekedni kell a vizelettartási és a merevedési képesség megőrzésére. = In Hungary, prostate cancer is the third most common cause of death in men with 4,500-4,800 newly diagnosed patients annually. The incidence is below the European average, but its mortality is much higher, which can also be explained by the lack of early detection. Early detected prostate cancer can be cured, the 5-year survival is almost 100%, while in metastatic form it is only 28%. There are several treatment options available for prostate cancer. However, as a curative and life-expectancy-enhancing therapy, only total prostatectomy can be recommended for high-risk patients with the life expectancy of at least 10 years. During radical prostatectomy, the prostate is removed, along with its capsule, seminal vesicles on both sides and pelvic lymph nodes. During surgery, efforts must be made to preserve urinary continence and erectile function

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer

OBJECTIVES: Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to docetaxel. Therefore, prediction of docetaxel resistance has become of great clinical importance. Syndecan-1 (SDC1) has been currently shown to be involved in chemotherapy resistance in various malignancies including prostate cancer. The predicting value of serum SDC1 level has not been evaluated yet. PATIENTS AND METHODS: We assessed the baseline levels of SDC1 in serum samples of 75 patients with CRPC who received docetaxel therapy until the appearance of therapy resistance. In one patient who was treated with three treatment series, we assessed also 6 additional serum samples collected during a 1-year treatment period. Serum SDC1 levels were correlated with clinical outcomes as well as with serum levels of MMP7. RESULTS: Pretreatment SDC1 serum levels were not associated with patients' age, the presence of bone or visceral metastases. In univariable analyses, patients' performance status, the presence of bone or visceral metastases, high pretreatment prostate specific antigen and SDC1 levels were significantly associated with cancer-specific survival. In multivariable analysis patients' performance status (P = 0.005), presence of bone or visceral metastases (P = 0.013) and high SDC1 level (P = 0.045) remained independent predictors of patients' survival. In the patient with available follow-up samples serum SDC1 level increased from 50 to 300ng/ml at radiographic progression. Serum concentrations of SDC1 were correlated with those of MMP7 (r = 0.420, P = 0.006). CONCLUSIONS: Our present results together with currently published data suggest a role for SDC1 shedding in chemotherapy resistance. Determination of serum SDC1 may contribute to the prediction of docetaxel resistance and therefore may help to facilitate clinical decision-making regarding the type and timing of therapy for patients with CRPC

Visual Communication in Shared Mobility Systems as an Opportunity for Recognition and Competitiveness in Smart Cities

Due to the intensive development of urbanization and digitization, the number of smart cities in the world is growing. Along with their exposure, more and more challenges are facing the service providers of the various types of systems offered in their area. These types of services include shared mobility systems that, as an alternative to transport by own vehicle, are becoming one of the leading promoted forms of mobility. Because of the prioritization of shared mobility solutions, more and more operators appear on the smart city markets, which is associated with many challenges related to the increased competition among service providers. One of the challenges is the appropriate visibility of the brand and vehicles in urban transport systems. This aspect, despite its high applicability, constitutes a research gap among world studies. Aiming to fill this gap, this article was dedicated to the issues of perception of visual communication by operators of shared mobility services. As part of the research, an expert study was conducted among representatives of shared mobility services operating in Poland. The expert survey was conducted with the Computer-Assisted Web Interview (CAWI) technique. The results of the research show that visual communication is not used quite correctly by operators. Although operators use single visual communication practices, overall consistency is lacking, which would add value to the brand. This article supports operators looking to expand their shared mobility services. What is more, it is also a response to the research gap regarding visual communication and its perception from the point of view of smart cities

Visual Communication in Shared Mobility Systems as an Opportunity for Recognition and Competitiveness in Smart Cities

Due to the intensive development of urbanization and digitization, the number of smart cities in the world is growing. Along with their exposure, more and more challenges are facing the service providers of the various types of systems offered in their area. These types of services include shared mobility systems that, as an alternative to transport by own vehicle, are becoming one of the leading promoted forms of mobility. Because of the prioritization of shared mobility solutions, more and more operators appear on the smart city markets, which is associated with many challenges related to the increased competition among service providers. One of the challenges is the appropriate visibility of the brand and vehicles in urban transport systems. This aspect, despite its high applicability, constitutes a research gap among world studies. Aiming to fill this gap, this article was dedicated to the issues of perception of visual communication by operators of shared mobility services. As part of the research, an expert study was conducted among representatives of shared mobility services operating in Poland. The expert survey was conducted with the Computer-Assisted Web Interview (CAWI) technique. The results of the research show that visual communication is not used quite correctly by operators. Although operators use single visual communication practices, overall consistency is lacking, which would add value to the brand. This article supports operators looking to expand their shared mobility services. What is more, it is also a response to the research gap regarding visual communication and its perception from the point of view of smart cities